Projects
Network analysis of analysis of disease phenotypes and drug responses KU Leuven
The pharmaceutical industry is facing unprecedented pressure to increase its productivity. Attrition rates in the later stages of development have risen sharply, with toxicity and lack of efficacy being the main bottlenecks. To address both these safety- and efficacy-related issues, a better understanding of the complex biological response to drug treatment is vital. Although many drugs exert their therapeutic activities through the ...
OrBITS Platform: A Cloud-Based Image Analysis and Drug Screening Service. University of Antwerp
Waste water analysis report on the stimulant illicit drug markets in the EU (WATCH). University of Antwerp
Europe-wide Sewage analysis to Monitor Emerging drug problems (EuSeME). University of Antwerp
Drug solubility in human intestinal fluids: multi-objective analysis and modelling KU Leuven
Estimation of drug abuse in Belgium by analysis of wastewater. University of Antwerp
Functional Precision Oncology: Next-generation treatment rationale for glioblastoma Mapping the drug response heterogeneity using single cell protein analysis KU Leuven
Glioblastoma (GBM) is the most aggressive brain cancer in adults. In spite of intensive treatment, median survival is still only 15 months. Reasons that explain failure to develop more efficient therapies include the high invasiveness of the tumor, its complex genetics, and interpatient and intra-tumoral heterogeneity. Understanding and mapping the complexity of the different tumour cell populations and how each of these respond to therapy, ...
Evaluation of drug abuse in Belgium by analysis of wastewater. University of Antwerp
Unraveling the multidrug resistance, drug tolerance, and collateral sensitivity in the emergent nosocomial fungus C. auris using experimental evolution and multi-omics analysis. KU Leuven
Antifungal resistance is rising on an unprecedented scale. Invasive, multidrug-resistant (MDR) fungal infections are threatening public health, and are further complicated by the availability of only three major antifungal drug classes. The novel species C. auris embodies this antifungal resistance crisis. Since its first identification in 2009, this opportunistic pathogen has emerged worldwide in various hospital outbreaks and it has shown ...